Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli (NA) 80078, Italy; Computational Bioscience Research Center, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.
Computational Bioscience Research Center, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia; Max Planck Institute for Molecular Genetics, Ihnestrasse 63-73, 14195 Berlin, Germany.
Stem Cell Reports. 2021 May 11;16(5):1381-1390. doi: 10.1016/j.stemcr.2021.03.028. Epub 2021 Apr 22.
Controlling cell fate has great potential for regenerative medicine, drug discovery, and basic research. Although transcription factors are able to promote cell reprogramming and transdifferentiation, methods based on their upregulation often show low efficiency. Small molecules that can facilitate conversion between cell types can ameliorate this problem working through safe, rapid, and reversible mechanisms. Here, we present DECCODE, an unbiased computational method for identification of such molecules based on transcriptional data. DECCODE matches a large collection of drug-induced profiles for drug treatments against a large dataset of primary cell transcriptional profiles to identify drugs that either alone or in combination enhance cell reprogramming and cell conversion. Extensive validation in the context of human induced pluripotent stem cells shows that DECCODE is able to prioritize drugs and drug combinations enhancing cell reprogramming. We also provide predictions for cell conversion with single drugs and drug combinations for 145 different cell types.
控制细胞命运对于再生医学、药物发现和基础研究具有巨大的潜力。尽管转录因子能够促进细胞重编程和转分化,但基于其上调的方法通常效率较低。能够促进细胞类型之间转化的小分子可以通过安全、快速和可逆的机制改善这一问题。在这里,我们提出了 DECODE,这是一种基于转录数据识别此类分子的无偏计算方法。DECODE 将大量药物诱导的药物处理谱与大量原代细胞转录谱数据集进行匹配,以识别单独或联合使用能够增强细胞重编程和细胞转化的药物。在人类诱导多能干细胞的背景下进行的广泛验证表明,DECODE 能够优先选择增强细胞重编程的药物和药物组合。我们还针对 145 种不同的细胞类型提供了使用单一药物和药物组合进行细胞转化的预测。